BPO 0.00% 0.3¢ bioprospect limited

great announcement+ down, page-5

  1. 3,958 Posts.
    lightbulb Created with Sketch. 492
    I think you are right, the market appears to be waiting on Qcide.
    For so long it has been branded as the flagship product for BPO, and yet very little has been announced.
    Furthermore, the last few announcements have been very positive (Tradewyns, AP778 patent), yet the price hasnt significantly broken out above the 14-15c level.

    The tradewyns announcement was excellent, and a great strategic move by the company IMO. Not only will they have more control over the distribution of the products they develop, but for a capital cost of only $2 million (at this stage), they are setting up a company they expect to generate significant revenues in the first year.

    The alternative was maybe spending 10-15 million on a cash flow positive company, and that would mean a further dilution for everyone's holdings. They certainly appear to have taken the smart strategic route with Tradewyns, and it will certainly enhance BPO's presence in the market place.

    Having said that the price has fallen following this announcement, and there is strong support at 10c. Not only was this the placement price from a couple of months ago, but there was accumulation at this level for almost 5 weeks. Even though we were red today, there was a short period where the depth looked vulnerable to dropping below 11c, but it didnt...

    But back to the original point.. the market appears to be waiting on news regarding Qcide, and this will be the primary factor in any significant movement in price.

    Time will tell..
 
watchlist Created with Sketch. Add BPO (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.